Nivolumab selectively blocks the interaction between PD-1 and PD-L1/Programmed Death-Ligand 2 expressed on tumor cells, disrupting PD-L1-mediated signaling and thereby restoring the antitumor response of effector T cells (51). The gene discussed is PDCD1; the disease is neoplasm.